AstraZeneca's Calquence (acalabrutinib), combined with bendamustine and rituximab, has received approval in the US for treating adult patients with previously untreated mantle cell lymphoma (MCL) who cannot undergo autologous hematopoietic stem...
Indian pharmaceutical company Zydus has been granted approval by the USFDA to perform a Phase II(b) clinical trial aimed at identifying the ideal dosage strength of Usnoflast, an innovative oral NLRP3 inflammasome inhibitor for individuals with...
Caris Life Sciences (Caris), a prominent next-generation AI TechBio firm and a leader in precision medicine, revealed a strategic and multifaceted partnership with Ontada, a company focused on oncology real-world evidence, clinical education, and...
Alcresta Therapeutics, Inc., a prominent company in the commercial stage that specializes in creating and marketing innovative enzyme-based products, announced that the US Food and Drug Administration (FDA) has approved the expanded utilization of...
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has authorized Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn's disease in adults. Omvoh has received approval in the US for two forms of...
Innovent Biologics, Inc. (Innovent), a premier biopharmaceutical firm that develops, produces, and markets high-quality medications for treating oncology, cardiovascular and metabolic disorders, autoimmune diseases, ophthalmology, and other...
Taro Pharma, the US division of India's top drug maker Sun Pharmaceuticals Ltd., has reached a agreement with Antibe Therapeutics, a biotech firm from Canada. After the announcement, Sun Pharmaceuticals has agreed to acquire 100% share in Antibe...
Gland Pharma announced that it has secured the establishment inspection report (EIR) from the US drug regulatory authority for its Dundigal site in Hyderabad, marking the conclusion of the inspection. The US Food and Drug Administration (USFDA)...
Annovis Bio Inc., a company in the late stages of clinical drug development focused on innovative therapies for neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD), revealed that it received the US patent for...
PulseSight Therapeutics SAS, a biotech firm focused on ophthalmology that creates groundbreaking non-viral vector therapies utilizing minimally-invasive delivery methods, has announced it has filed a Clinical Trial Authorization (CTA) with the...
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")